The United States remains ahead of China in biotechnology, but its advantage is shrinking, according to the latest Biotech Scorecard from the Special Competitive Studies Project (SCSP), a nonprofit and nonpartisan initiative aimed at strengthening America's long-term competitiveness in artificial intelligence. The report, released by (NewsUSA), evaluates the two countries across five dimensions: Innovation Leadership, Market Ecosystem, Talent Pipeline, Industrial Capacity, and National Leverage.
The U.S. leads in Innovation Leadership, Market Ecosystem, and Talent Pipeline, but China appears ahead in Industrial Capacity and National Leverage. This edge could allow China to overtake the U.S. in biotechnology by 2030, the report warns, citing two decades of deliberate national strategy that is now producing results. By contrast, the American position is described as “a return on research investments made decades ago, sustained by a capital market that rewards its strongest performers.”
The scorecard focuses on the biopharmaceuticals sector as an example of China's acceleration. Most U.S. government funding for biotechnology goes to basic research, and the report notes a lack of urgency in expanding government support for commercializing drug products. “Approval timelines for drugs entering clinical trials and going to domestic markets are driven by government policy, and can help accelerate, or slow down, the pipeline of innovation,” the SCSP authors emphasize.
While both countries invest in basic research, China is more active in supporting biotech startups through the process of acquiring capital to build pilot capacity, scale up production, and reach markets, without waiting for a definitive return on these expanded investments. This strategy includes preferential taxation, below-market lending, and direct subsidies. The U.S. tends to leave this aspect of biotechnology development to the private sector.
Looking ahead, as artificial intelligence allows scientists to predict molecular activity, the expensive early stages of drug discovery will likely decrease, and the competitive advantage will shift to testing, manufacturing, and commercializing a promising drug candidate. “Whether the United States retains its edge depends both on model quality and how quickly it can move a computationally generated candidate through trials, approval, and manufacture before a competitor improves on it,” according to the report.
The implications are significant: the U.S. could lose its biotech leadership if it does not address gaps in industrial capacity and national leverage. The report suggests that government policy on approval timelines and support for commercialization could be critical in determining whether the U.S. maintains its edge. To read the full report and learn more, visit scsp.ai.
